Skip to main content

Generic Combigan Availability

Last updated on Nov 8, 2022.

Combigan is a brand name of brimonidine/timolol ophthalmic, approved by the FDA in the following formulation(s):

COMBIGAN (brimonidine tartrate; timolol maleate - solution/drops;ophthalmic)

  • Manufacturer: ALLERGAN
    Approval date: October 30, 2007
    Strength(s): 0.2%;EQ 0.5% BASE [RLD] [AB]

Has a generic version of Combigan been approved?

A generic version of Combigan has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Combigan and have been approved by the FDA:

BRIMONIDINE TARTRATE AND TIMOLOL MALEATE (brimonidine tartrate; timolol maleate solution/drops;ophthalmic)

  • Manufacturer: AKORN
    Approval date: October 31, 2022
    Strength(s): 0.2%;EQ 0.5% BASE [AB]
  • Manufacturer: APOTEX INC
    Approval date: April 20, 2022
    Strength(s): 0.2%;EQ 0.5% BASE [AB]
  • Manufacturer: SANDOZ INC
    Approval date: April 4, 2022
    Strength(s): 0.2%;EQ 0.5% BASE [AB]
  • Manufacturer: WATSON LABS TEVA
    Approval date: October 4, 2022
    Strength(s): 0.2%;EQ 0.5% BASE [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Combigan. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Combination of brimonidine timolol for topical ophthalmic use
    Patent 7,030,149
    Issued: April 18, 2006
    Inventor(s): Chang; Chin-Ming & Beck; Gary J. & Pratt; Cynthia C. & Batoosingh; Amy L.
    Assignee(s): Allergan, Inc.

    Disclosed are pharmaceutical compositions comprising brimondine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressure in the eyes of humans.

    Patent expiration dates:

    • April 19, 2022
      ✓ 
      Patent use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP. DOSE IS ONE DROP OF COMBIGAN IN THE AFFECTED EYE TWICE DAILY
  • Combination of brimonidine and timolol for topical ophthalmic use
    Patent 7,320,976
    Issued: January 22, 2008
    Inventor(s): Chang; Chin-Ming & Beck; Gary J. & Pratt; Cynthia C. & Batoosingh; Amy L.
    Assignee(s): Allergan, Inc.

    Disclosed are pharmaceutical compositions comprising brimondine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressure in the eyes of humans.

    Patent expiration dates:

    • April 19, 2022
      ✓ 
      Patent use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP. DOSE IS ONE DROP OF COMBIGAN IN THE AFFECTED EYE TWICE DAILY
  • Combination of brimonidine and timolol for topical ophthalmic use
    Patent 7,642,258
    Issued: January 5, 2010
    Inventor(s): Chang; Chin-Ming & Beck; Gary J. & Pratt; Cynthia C. & Batoosingh; Amy L.
    Assignee(s): Allergan, Inc.

    Disclosed are pharmaceutical compositions comprising brimondine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressure in the eyes of humans.

    Patent expiration dates:

    • April 19, 2022
      ✓ 
      Patent use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Combination of brimonidine and timolol for topical ophthalmic use
    Patent 8,133,890
    Issued: March 13, 2012
    Inventor(s): Chang; Chin-Ming & Beck; Gary J. & Pratt; Cynthia C. & Batoosingh; Amy L.
    Assignee(s): Allergan, Inc.

    Disclosed are pharmaceutical compositions comprising brimondine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressure in the eyes of humans.

    Patent expiration dates:

    • April 19, 2022
      ✓ 
      Patent use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION
  • Combination of brimonidine and timolol for topical ophthalmic use
    Patent 8,354,409
    Issued: January 15, 2013
    Assignee(s): Allergan, Inc.

    Disclosed are pharmaceutical compositions comprising brimondine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressure in the eyes of humans.

    Patent expiration dates:

    • April 19, 2022
      ✓ 
      Patent use: REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH ELEVATED INTRAOCULAR PRESSURE OR GLAUCOMA
      ✓ 
      Drug product
  • Combination of brimonidine and timolol for topical ophthalmic use
    Patent 8,748,425
    Issued: June 10, 2014
    Assignee(s): Allergan Sales, LLC

    Disclosed are pharmaceutical compositions comprising brimondine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressure in the eyes of humans.

    Patent expiration dates:

    • April 19, 2022
      ✓ 
      Patent use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
      ✓ 
      Drug product
  • Combination of brimonidine and timolol for topical ophthalmic use
    Patent 9,474,751
    Issued: October 25, 2016
    Assignee(s): ALLERGAN SALES, LLC

    Disclosed are pharmaceutical compositions comprising brimonidine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressure in the eyes of humans.

    Patent expiration dates:

    • April 19, 2022
      ✓ 
      Patent use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
      ✓ 
      Drug product
  • Combination of brimonidine and timolol for topical ophthalmic use
    Patent 9,770,453
    Issued: September 26, 2017
    Assignee(s): ALLERGAN SALES, LLC

    Disclosed are pharmaceutical compositions comprising brimonidine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressure in the eyes of humans.

    Patent expiration dates:

    • April 19, 2022
      ✓ 
      Patent use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION, WITH COMPARABLE EFFICACY, AND A REDUCTION IN SPECIFIED ADVERSE EVENTS, COMPARED TO BRIMONIDINE 0.2% TID
      ✓ 
      Drug product
  • Combination of brimonidine and timolol for topical ophthalmic use
    Patent 9,907,801
    Issued: March 6, 2018
    Assignee(s): ALLERGAN SALES, LLC

    Disclosed are pharmaceutical compositions comprising brimonidine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressure in the eyes of humans.

    Patent expiration dates:

    • April 19, 2022
      ✓ 
      Patent use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION, WITH A REDUCTION IN SPECIFIED ADVERSE EVENTS, COMPARED TO BRIMONIDINE 0.2% TID
      ✓ 
      Drug product
  • Combination of brimonidine and timolol for topical ophthalmic use
    Patent 9,907,802
    Issued: March 6, 2018
    Assignee(s): ALLERGAN SALES, LLC

    Disclosed are pharmaceutical compositions comprising brimonidine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressure in the eyes of humans.

    Patent expiration dates:

    • April 19, 2022
      ✓ 
      Patent use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION, WITH COMPARABLE EFFICACY TO BRIMONIDINE 0.2% TID
      ✓ 
      Drug product

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
AB Products meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (e.g. identical active ingredients, dosage form, and routes of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (e.g. AB1, AB2, AB7). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.